(ACB) Aurora Cannabis - Overview
Stock: Cannabis, Oils, Capsules, Edibles, Concentrates
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.4% |
| Relative Tail Risk | -22.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -61.83 |
| Character TTM | |
|---|---|
| Beta | 1.297 |
| Beta Downside | 1.197 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.60% |
| CAGR/Max DD | -0.38 |
Description: ACB Aurora Cannabis January 01, 2026
Aurora Cannabis Inc. (NASDAQ:ACB) is a vertically integrated cannabis producer headquartered in Edmonton, Canada. It operates two segments-Canadian Cannabis and Plant Propagation-offering a broad portfolio that spans pharmaceutical-grade medical products, consumer-focused dried flower, oils, concentrates, edibles, vaporizers, topicals, and plant propagation services. Its brand lineup includes domestic names such as San Rafael ’71, Greybeard, and Aurora, as well as international labels like Pedanios and CraftPlant.
As of FY 2023, Aurora generated roughly $1.3 billion in revenue but posted a net loss of about $1.0 billion, reflecting ongoing cost-structure challenges and price compression in the Canadian market. The company’s production capacity now exceeds 100,000 kg of dried flower per year, and its cash balance sits near $350 million, giving it limited runway without further financing. Key economic drivers include the pace of Canadian regulatory reforms (e.g., potential expansion of adult-use retail), the opening of U.S. medical markets, and the broader macro trend of cannabis legalization that continues to lift demand forecasts across North America.
For a deeper, data-driven view of Aurora’s valuation and risk profile, you might explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 40.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 83.05% < 20% (prev 107.5%; Δ -24.45% < -1%) |
| CFO/TA -0.01 > 3% & CFO -9.60m > Net Income 40.6m |
| Net Debt (44.6m) to EBITDA (76.0m): 0.59 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.3m) vs 12m ago 2.82% < -2% |
| Gross Margin: 62.72% > 18% (prev 0.68%; Δ 6205 % > 0.5%) |
| Asset Turnover: 44.01% > 50% (prev 36.97%; Δ 7.03% > 0%) |
| Interest Coverage Ratio: 6.27 > 6 (EBITDA TTM 76.0m / Interest Expense TTM 8.43m) |
Altman Z'' -15.00
| A: 0.39 (Total Current Assets 445.8m - Total Current Liabilities 145.9m) / Total Assets 775.3m |
| B: -8.26 (Retained Earnings -6.40b / Total Assets 775.3m) |
| C: 0.06 (EBIT TTM 52.8m / Avg Total Assets 820.6m) |
| D: 1.82 (Book Value of Equity 377.6m / Total Liabilities 207.5m) |
| Altman-Z'' Score: -22.05 = D |
Beneish M -3.10
| DSRI: 0.79 (Receivables 44.2m/49.5m, Revenue 361.1m/320.2m) |
| GMI: 1.08 (GM 62.72% / 67.74%) |
| AQI: 0.77 (AQ_t 0.09 / AQ_t-1 0.12) |
| SGI: 1.13 (Revenue 361.1m / 320.2m) |
| TATA: 0.06 (NI 40.6m - CFO -9.60m) / TA 775.3m) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of ACB shares?
Over the past week, the price has changed by -8.42%, over one month by -15.13%, over three months by -23.13% and over the past year by -45.69%.
Is ACB a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.4 | 77.7% |
| Analysts Target Price | 6.4 | 77.7% |
| ValueRay Target Price | 2.8 | -20.9% |
ACB Fundamental Data Overview February 08, 2026
P/E Forward = 17.4216
P/S = 0.5289
P/B = 0.5045
Revenue TTM = 361.1m CAD
EBIT TTM = 52.8m CAD
EBITDA TTM = 76.0m CAD
Long Term Debt = 40.2m CAD (from longTermDebt, last fiscal year)
Short Term Debt = 67.8m CAD (from shortTermDebt, last quarter)
Debt = 101.0m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 44.6m CAD (from netDebt column, last quarter)
Enterprise Value = 262.1m CAD (269.5m + Debt 101.0m - CCE 108.5m)
Interest Coverage Ratio = 6.27 (Ebit TTM 52.8m / Interest Expense TTM 8.43m)
EV/FCF = -8.38x (Enterprise Value 262.1m / FCF TTM -31.3m)
FCF Yield = -11.93% (FCF TTM -31.3m / Enterprise Value 262.1m)
FCF Margin = -8.66% (FCF TTM -31.3m / Revenue TTM 361.1m)
Net Margin = 11.24% (Net Income TTM 40.6m / Revenue TTM 361.1m)
Gross Margin = 62.72% ((Revenue TTM 361.1m - Cost of Revenue TTM 134.6m) / Revenue TTM)
Gross Margin QoQ = 49.50% (prev 89.57%)
Tobins Q-Ratio = 0.34 (Enterprise Value 262.1m / Total Assets 775.3m)
Interest Expense / Debt = 2.08% (Interest Expense 2.10m / Debt 101.0m)
Taxrate = 22.66% (4.62m / 20.4m)
NOPAT = 40.9m (EBIT 52.8m * (1 - 22.66%))
Current Ratio = 3.06 (Total Current Assets 445.8m / Total Current Liabilities 145.9m)
Debt / Equity = 0.19 (Debt 101.0m / totalStockholderEquity, last quarter 536.4m)
Debt / EBITDA = 0.59 (Net Debt 44.6m / EBITDA 76.0m)
Debt / FCF = -1.43 (negative FCF - burning cash) (Net Debt 44.6m / FCF TTM -31.3m)
Total Stockholder Equity = 546.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.95% (Net Income 40.6m / Total Assets 775.3m)
RoE = 7.43% (Net Income TTM 40.6m / Total Stockholder Equity 546.7m)
RoCE = 9.00% (EBIT 52.8m / Capital Employed (Equity 546.7m + L.T.Debt 40.2m))
RoIC = 6.72% (NOPAT 40.9m / Invested Capital 607.6m)
WACC = 8.22% (E(269.5m)/V(370.5m) * Re(10.69%) + D(101.0m)/V(370.5m) * Rd(2.08%) * (1-Tc(0.23)))
Discount Rate = 10.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 61.83%
Fair Price DCF = unknown (Cash Flow -31.3m)
EPS Correlation: 56.08 | EPS CAGR: 319.8% | SUE: -0.32 | # QB: 0
Revenue Correlation: 91.68 | Revenue CAGR: 18.13% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.08 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2027-03-31): EPS=-0.05 | Chg30d=-0.162 | Revisions Net=-1 | Growth EPS=+95.9% | Growth Revenue=-4.5%